Active immunization for treating atopic dermatitis
Patent Information
- Application Number
- HK62026125764
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-19
- Filing Date
- 2026-07-06
- Publication Date
- 2026-09-11
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
Abstract: An immunogenic fusion protein for active immunization or a bivalent vaccine for treating atopic dermatitis (AD) in an individual, and its method thereof. The immunogenic fusion protein comprises an IL31 polypeptide and at least one substance, a P polypeptide (SP). Specifically, this invention can be used for the treatment and / or prevention of AD and AD-related symptoms in mammals, including pruritus.
Claims
WE CLAIM1. An immunogenic fusion protein comprising: at least one IL31 polypeptide (IL31) or immunogenic fragment thereof; and at least one substance P polypeptide (SP), wherein said immunogenic fusion protein is capable of eliciting a production of neutralizing polyclonal antibodies against IL31 and SP.
2. The immunogenic fusion protein of claim 1, wherein an administering in a mammal of said immunogenic fusion protein yields higher neutralizing antibody titers compared to that of a combination of a non-fused IL31 polypeptide and a non-fused SP peptide administered as single agents.
3. The immunogenic fusion protein of claim 1, wherein said at least one IL31 polypeptide comprises an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 SEQ ID NO: 4, or an immunogenic fragment thereof.
4. The immunogenic fusion protein of any of claims 1-3, wherein said at least one SP peptide comprises an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, or SEQ ID NO: 9.
5. The immunogenic fusion protein of claim 4, wherein said at least one SP peptide is one, three or five SP peptides.
6. The immunogenic fusion protein of claim 1, comprising one IL-31 polypeptide or immunogenic fragment thereof, fused to one, three or five SP peptides.
7. The immunogenic fusion protein of claim 6, comprising one IL31 polypeptide fused to one SP peptide, optionally linked with peptide linkers.
8. The immunogenic fusion protein of claim 7, wherein said at least one SP peptide and at least one IL31 polypeptide or immunogenic fragment thereof are fused by a flexible peptide linker GSGS.
9. The immunogenic fusion protein of claim 7, comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23 or SEQ ID NO: 29.
10. The immunogenic fusion protein of claim 6, comprising one IL31 polypeptide and three SP peptides, optionally linked with peptide linkers.
11. The immunogenic fusion protein of claim 10, comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 14, SEQ ID NO: 20, SEQ ID NO: 26 or SEQ ID NO: 32.
12. The immunogenic fusion protein of claim 6, comprising one IL31 polypeptide and five SP peptides, optionally linked with peptide linkers.
13. A recombinant vector comprising at least a nucleotide encoding the immunogenic fusion protein of any of claims 1-12.
14. The recombinant vector of claim 13, comprising a nucleotide sequence encoding for said immunogenic fusion protein having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 10, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 22, SEQ ID NO: 25, SEQ ID NO: 28 or SEQ ID NO: 31.
15. The recombinant vector of claim 13, comprising a nucleotide sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 27 or SEQ ID NO: 33.
16. A method for producing the immunogenic fusion protein of any of claims 1-12, wherein said immunogenic fusion protein is produced in a procaryotic or eukaryotic expression system.
17. The method of claim 16, wherein the immunogenic fusion protein is produced in a procaryotic expression system as inclusion bodies, said immunogenic fusion protein being solubilized in high molar concentrations of urea.
18. The method of claim 16, wherein the recombinant vector comprises a nucleotide sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to one of SEQ ID NO: 12, SEQ ID NO: 18, SEQ ID NO: 24, SEQ ID NO: 30, SEQ ID NO: 15, SEQ ID NO: 21, SEQ ID NO: 27 or SEQ ID NO: 33.
19. An immunogenic composition comprising at least one immunogenic fusion protein of any one of claims 1-12.
20. An immunogenic composition produced according to the method of any of claims 16-18.
21. The immunogenic composition of claim 19, further comprising an acceptable carrier and / or an adjuvant selected from the group consisting of oil-in-water adjuvant, polymer and water adjuvant, water-in-oil adjuvant, aluminum hydroxide adjuvant and combinations thereof.
22. The immunogenic composition of claim 21, wherein the adjuvant is a complete or incomplete Freund’s adjuvant, a Montanide™, Gel 01 PR, aluminum salts (alum), oil emulsions, saponins, immune -stimulating complexes (ISCOMs), liposomes, microparticles, nonionic block copolymers, derivatized polysaccharides, cytokines, or bacterial derivatives.
23. The immunogenic composition of any of claims 19-22 for use as a medicament, preferably a vaccine.
24. The immunogenic composition of claim 23 for use in the treatment and / or the prevention of inflammation in pruritus-related skin disorder, preferably AD, most preferably chronic and / or refractory AD.
25. The immunogenetic composition for use according to claim 24, wherein AD is refractory to at least one anti-inflammatory compound selected from the group consisting of a corticosteroid, an antihistamine, a tyrosine kinase inhibitor and cyclosporine.
26. A pharmaceutical composition for treating or preventing AD and / or AD-related symptoms in a subject comprising at least one immunogenic fusion protein of any of claims 1-12 and a pharmaceutically acceptable carrier.
27. The pharmaceutical composition of claim 26, wherein AD-related symptoms are pruritus and / or secondary skin lesions.
28. The pharmaceutical composition of claim 27, wherein AD is refractory to at least one anti-inflammatory compound selected from the group consisting of a corticosteroid, an antihistamine, a tyrosine kinase inhibitor and cyclosporine.
29. A method for treating or preventing AD and or AD-related symptoms in a mammal comprising administering an effective amount of the immunogenic composition of any of claims 19-22.
30. The method of claim 29, wherein the AD-related symptoms are pruritus and / or secondary skin lesions.
31. The method of claim 29, wherein the administering of said effective amount of the immunogenic composition results in the reduction of a pruritus score, said pruritus score being determined using a pruritus scale as defined in Fig. 6A (e.g., scratching, biting, licking, and rubbing against objects or the floor).
32. The method of claim 29, wherein the AD-related symptoms are refractory to at least one anti-inflammatory compound selected from the group consisting of a corticosteroid, an antihistamine, a tyrosine kinase inhibitor and cyclosporine.
33. The method of any of claims 29-31, wherein the immunogenic composition is administered in combination with at least one anti-inflammatory compound selected from the group consisting of a corticosteroid, an antihistamine, a tyrosine kinase inhibitor and cyclosporine.
34. The method of any of claims 29-33, wherein the immunogenic composition is administered in combination with at least one receptor antagonist that blocks a nociceptive signaling pathway, preferably a neurokinin- 1 receptor (NKl-R) antagonist, most preferably compound CP-96,345.
35. The method of any of claims 29-34, wherein said immunogenic composition is administered orally, subcutaneously, intramuscularly, or transdermally, preferentially subcutaneously.
36. The method of any of claims 29-35, wherein said immunogenic composition is administered as a priming dose followed by three booster doses administered approximately 2 weeks apart, and optionally followed by one or more booster doses administered 3 to 6 months apart, or over a period of time required to sustain high neutralizing antibody titers.
37. The method of any of claims 29-36, wherein the mammal is a canine, human, feline or equine.
38. A method for treating or preventing AD or AD-associated symptoms in a dog comprising the subcutaneous administering of a bivalent vaccine as a priming dose followed by three booster doses administered approximately 2 weeks apart, and optionally followed by one or more booster doses administered 3 to 6 months apart, or over a period of time required to sustain high neutralizing antibody titers, wherein said bivalent vaccine comprises an immunogenic fusion protein IL31- SP comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 or an immunogenic fusion protein IL31- 3SP comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to SEQ ID NO: 14.
39. A bivalent vaccine for treating or preventing an inflammation-related skin disorder, preferably AD or AD-associated symptoms in mammals comprising the immunogenic fusion protein of any of claims 1-12.
40. A bivalent vaccine for treating or preventing AD and / or pruritus in dogs comprising an immunogenic fusion protein IL31-1SP comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to SEQ ID NO: 11 or an immunogenic fusion protein IL31-3SP comprising an amino acid sequence having at least 90%, at least 95%, at least 99%, or 100% sequence identity to SEQ ID NO: 14.
